Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate

B. Melegh, J. Kerner, V. Jaszai, L. L. Bieber

Research output: Contribution to journalArticle

39 Citations (Scopus)


The fate of supplemental carnitine was studied in human subjects treated with drugs known to cause carnitine deficiency. Six children were treated with pivampicillin and equimolar l-carnitine for 7 days. On the last day of treatment, the plasma levels of total and free carnitine were decreased, but acylcarnitine levels were increased. A 12-fold increase in urinary excretion of acylcarnitines was found; it increased from 188.5 ± 82.7 to 2218.4 ± 484.1 μmole/day, and 84% was pivaloylcarnitine. Free carnitine excretion was reduced. Ten epileptic children on chronic valproate treatment received equimolar carnitine for a 2-week period. Plasma carnitine levels were elevated on the last day of treatment. A 3.4-fold increase in urinary acylcarnitines was found, but most of the excreted carnitines were free (64.5-fold increases). These data show that pivalate is readily converted to carnitine esters, in contrast to the limited conversion of valproate to acylcarnitines in humans.

Original languageEnglish
Pages (from-to)30-38
Number of pages9
JournalBiochemical Medicine and Metabolic Biology
Issue number1
Publication statusPublished - Feb 1990


ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry

Cite this